Approximately 7% of patients with non–small cell lung cancer (NSCLC) present with a limited number of metastatic foci.
1 Weichselbaum and Hellman
2 have hypothesized that cancer metastasis falls on a continuum. Although some malignant neoplasms are localized and others are systemic from diagnosis, most will fall between these 2 extremes.
2 Within this revised paradigm of tumor metastasis, the concept of treating a limited number of metastatic lesions with curative intent becomes rational, because their mere presence no longer excludes the possibility of long-term disease control or even cure. Multiple retrospective studies in oligometastatic NSCLC
3,4 have shown that the use of locally ablative therapy (LAT) to all sites of disease is associated with a significant improvement in overall survival (OS) and progression-free survival (PFS) when compared with historical data.